Asian Journal of Pharmaceutical Research
  • Year: 2021
  • Volume: 11
  • Issue: 2

COVID 19 and its management

Royal School of Pharmacy, The Assam Royal Global University, Guwahati, India

*Corresponding Author E-mail: subhashis.ooty@gmail.com

Online published on 8 June, 2021.

Abstract

In December 2019, severe acute respiratory syndrome-coronavirus-2, a novel coronavirus, initiated an outbreak of pneumonia from Wuhan in China, which rapidly spread worldwide. The outbreak was declared as “a public health emergency of international concern” by the WHO on January 30, 2020, and as a pandemic on March 11, 2020. The disease is transmitted by inhalation or contact with infected droplets and the incubation period ranges from 2 to 14 d. The symptoms are usually fever, cough, sore throat, breathlessness, fatigue, malaise among others. The disease is mild in most people; in some (usually the elderly and those with comorbidities), it may progress to pneumonia, acute respiratory distress syndrome (ARDS) and multi organ dysfunction. Many people are asymptomatic. The virus spreads faster than its two ancestors the SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), but has lower fatality.

Keywords

Coronavirus disease-19, Drug repurposing, Pandemic, Severe acute respiratory syndrome-coronavirus-2